Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate

[1]  I. Smith,et al.  High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. , 1987, European journal of cancer & clinical oncology.

[2]  T. Thorsen,et al.  Alterations in the Metabolism of Oestrogens During Treatment with Aminoglutethimide in Breast Cancer Patients , 1987, Clinical pharmacokinetics.

[3]  M. Knuiman,et al.  Combination hormone therapy for metastatic breast cancer: An ECOG study of megestrol and aminoglutethimide , 1987, Cancer.

[4]  A. Stockdale,et al.  Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations. , 1987, Cancer treatment reports.

[5]  U. Kleeberg,et al.  Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer: A phase II study of the association of medical oncology of the German cancer society (AIO) , 1986, Cancer.

[6]  P. Lønning,et al.  Aminoglutethimide as an inducer of microsomal enzymes. Part 1: Pharmacological aspects. , 1986, Breast cancer research and treatment.

[7]  G. Blijham,et al.  Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. , 1985, Cancer treatment reports.

[8]  P. Knapstein,et al.  Oral high-dose medroxyprogesterone acetate (MPA) treatment: cortisol/MPA serum profiles in relation to breast cancer regression. , 1985, Oncology.

[9]  M. Dowsett,et al.  LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCER , 1984, The Lancet.

[10]  T. Priestman,et al.  An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer. , 1984, British Journal of Cancer.

[11]  F. Pannuti,et al.  Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients. , 1982, Cancer treatment reports.

[12]  G. Nagel,et al.  Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. , 1982, Cancer research.

[13]  R. Santen,et al.  A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. , 1982, Cancer.

[14]  M. Tattersall,et al.  Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. , 1982, Cancer research.

[15]  R. Santen,et al.  Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. , 1982, Annals of internal medicine.

[16]  H. Portengen,et al.  Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. , 1980, Cancer research.

[17]  R. Santen,et al.  Serum Aminoglutethimide Levels: Studies of Serum Half‐Life, Clearance, and Patient Compliance , 1979, Journal of clinical pharmacology.

[18]  T. Powles,et al.  AMINOGLUTETHIMIDE IN TREATMENT OF METASTATIC BREAST CARCINOMA , 1978, The Lancet.

[19]  J. Evans,et al.  Radioimmunoassay for medroxyprogesterone acetate (Provera) using the 11alpha-hydroxy succinyl conjugate. , 1974, Steroids.

[20]  P. Nicholls,et al.  The urinary excretion of aminoglutethimide in man , 1965 .